A detailed history of Amundi transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Amundi holds 19,833 shares of DVAX stock, worth $218,163. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,833
Previous 22,942 13.55%
Holding current value
$218,163
Previous $284,000 21.83%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.73 - $12.58 $33,359 - $39,111
-3,109 Reduced 13.55%
19,833 $222,000
Q1 2024

May 15, 2024

BUY
$11.7 - $14.98 $69,088 - $88,456
5,905 Added 34.66%
22,942 $284,000
Q4 2023

Feb 14, 2024

BUY
$13.09 - $14.98 $9,856 - $11,279
753 Added 4.62%
17,037 $238,000
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $15,142 - $17,958
1,198 Added 7.94%
16,284 $240,000
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.17 $148,597 - $198,682
15,086 New
15,086 $194,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.39B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.